Since STING expression is heterogenous in TNBC cancer cells and tumors [6,43], this prompted the hypothesis that eribulin could augment the IFNβ response initiated by STING agonists in TNBC cells with a functional STING pathway. The gene discussed is IFNB1; the disease is cancer.